Introduction
Staphylococcus aureus is primarily a human pathogen, causing a broad spectrum of diseases ranging from septicaemia to localised skin infections. Both S. aureus and coagulase-negative staphylococci (CNS) form part of the normal skin micro¯ora. CNS strains were formerly regarded as opportunist pathogens, inducing systemic infections in immunocompromised patients [1] . However, CNS cause more infections of medical devices than any other group of micro-organisms and have emerged as the most frequently isolated pathogens of nosocomial sepsis [1, 2] . They may also give rise to endocarditis, endophthalmitis, osteomyelitis and urinary tract infections.
Several virulence factors have been identi®ed in S. aureus [3, 4] including different toxins and haemoly-sins, tissue-degrading enzymes, coagulase and ®brinogen-binding proteins, and several surface proteins which mediate adhesion to extracellular matrix (ECM) proteins such as ®bronectin (Fn), vitronectin (Vn), collagen (Cn), thrombospondin (TSP), laminin and plasminogen [5] .
Current concepts on the pathogenesis of wound and biomaterial-associated infections caused by CNS have focused on various interactions between staphylococci and host ECM proteins or serum components [6] . An earlier study showed that CNS strains bind ECM proteins in immobilised rather than soluble form and often bind immobilised proteins at higher levels than S. aureus [5] . This may be particularly relevant in biomaterial-associated infections, as host proteins immediately adsorb to the biomaterial surface and are thus present in immobilised forms [6] .
Two surface proteins of S. aureus with mol. wts of 66 and 60 kDa, respectively, were earlier identi®ed as binding heparan sulphate (HS) and heparin [7] . Also, CNS may interact with heparin and HS, as shown for whole staphylococcal cells which bound avidly to heparinised polymer surfaces [8] , or to heparin immobilised on latex particles [9] . The ability of both S. aureus and CNS strains to bind the heparin-binding growth factors, basic ®broblast growth factor (bFGF) and platelet-derived growth factor (PDGF) has also been shown [10] .
Heparin and HS constitute a class of glycosaminoglycans (GAGs) with common structural features [11] . The polysaccharide chains in heparin and HS proteoglycans are composed of partially sulphated, alternating hexuronic (L-iduronic or D-glucuronic) acid and Dglucosamine (N-sulphated or N-acetylated) residues. They differ as follows: heparin is highly sulphated and rich in L-iduronic acid, whereas HS is less sulphated and is rich in D-glucuronic acid. HS is located on the surface of most eukaryotic cells and forms part of the ECM [12] , whereas heparin is stored intracellularly, mainly in mast cells, and is released upon external signalling. By binding to antithrombin III, which interacts with thrombin, heparin exerts an anticoagulative effect. However, the anticoagulant activity of HS is much lower than that of heparin [13] . Interestingly, a number of growth factors require binding to heparin and cell surface HS upon their activation during tissue repair. During wound healing in human skin, a correlation between expression of basement membrane HS and normal epidermal proliferation was observed [14] .
This report describes the isolation of a 17-kDa heparinbinding surface protein from CNS.
Materials and methods

Chemicals
Heparin (mol. wt 4000±6000) was purchased from Fluka (Heidelberg, Germany). A Heparin-HiTrap, column (5 ml) was obtained from Pharmacia Biotech, Uppsala, Sweden. Thrombospondin (TSP) and von Willebrand Factor (vWF) were gifts from Professors J. Lawler and F. Dorner, respectively. Rabbit anti-human TSP, vWF, Fg, Fn and Vn, and peroxidase (HRP)conjugated goat anti-mouse IgG and HRP-swine antirabbit IgG were purchased from Dako (Glostrup, Denmark). Amino-carbazole, 5([4,6-dichlorotriazin-2yl]amino)¯uorescein (DTAF), basic ®broblast growth factor (bFGF) human recombinant, chondroitin 4sulphate, monoclonal anti-bFGF antibody, long-arm biotin-hydrazide, bovine serum albumin, cholera toxin, dextran sulphate (mol. wt 8000), fucoidan, hyaluronic acid from bovine trachea, pentosan polysulphate, sodium acetate, sodium periodate, HRP-conjugated streptavidin and toluidine blue were obtained from Sigma. Fragmin1 (low molecular heparin; mol. wt 5000) was purchased from Kabi AB (Stockholm, Sweden). Suramin (Germanin1) was from Bayer AG (Leverkusen, Germany) and Tween 20 from Merck AG (Darmstadt, Germany). Blood Agar (BA) base was purchased from Lab M (Salford) and supplemented with horse erythrocytes 4%. Tryptic Soy Broth (TS) was from Difco Laboratories (Detroit, MI, USA). All buffers and chemicals were of analytical grade.
Bacterial strains and growth conditions S. aureus strain V8, S. epidermidis strain RP 12, S. haemolyticus strain SM 131 and other strains of different CNS species, isolated from patients with osteomyelitis and biomaterial-associated infections (n 40) were studied [5] . S. saprophyticus strain TW 111, isolated from a patient with urinary tract infection and previously shown by agglutination assay [9] not to bind heparin was included as a negative control. CNS strains isolated from healthy carriers were also included. The test strains were cultured on BA at 378C for 20±22 h. Bacterial cells were harvested in the late stationary phase by centrifugation (1760 g for 20 min), washed twice with PBS, pH 7.2, and suspended in PBS at a ®nal concentration of 10 9 cfu=ml.
Biotinylation of staphylococci
Equal volumes of bacteria and biotin (EZ-Link-Sulfo-NHS-LC-biotin, Boule Nordic AB Stockholm, Sweden) solution (0:2 mg=ml in PBS, pH 7.6) were incubated for 2 h at ambient temperature. The staphylococcal cells were then washed three times with PBS and resuspended at the original concentration in PBS containing bovine serum albumin (BSA) 1%.
Cell surface extracts
For extraction of cell-surface components, cells of strain S. epidermidis RP 12, S. haemolyticus SM 131 and S. aureus V8 were washed twice in PBS, resuspended in 2.5 ml of 1.0 M LiCl, supplemented with protease inhibitors (Complete TM Mini, Boehringer Mannheim, Germany) and incubated for 2 h at 378C with agitation [7] . After centrifugation (8827 g, 30 min) the supernates were dialysed against PBS for 2 h at 48C. The protein content was determined by a BioRad microassay (BioRad, Richmond, CA, USA), with BSA as a standard. The crude LiCl extracts were stored at À208C.
Preparation of 125 1-DTAF-heparin and biotinylated heparin
To enable iodine labelling, DTAF was conjugated to heparin as described previously [15] . DTAF-heparin was dissolved in PBS at a concentration of 1±2 mg=ml. The pellet was lyophilised and stored dry at 48C. DTAF-heparin was iodinated with Na 125 I (Radiochemical Centre, Amersham) and Iodo-beads (Pierce Chemical Company, Rockford, IL, USA) according to the method of Pascu et al. [10] . Heparin was 548 C. FALLGREN, M. UTT AND A Ê . LJUNGH biotinylated as described by Utt and Wadstro Èm [16] . Biotinylated heparin was dissolved in water (1 mg=ml) and used as a stock solution.
Immobilised GAG-binding assay
Nunc-Maxisorp 96-well microtitration plates were covalently coupled with heparin, chondroitin 4-sulphate and dextran sulphate by end-point attachment (EPA) [17] . The presence of GAGs on the microtitration plates was detected by a chromatic method with toluidine blue stain [17] . Brie¯y, a positive chromatic reaction was detected when the well coated with GAGs was stained violet compared with the colour of uncoated wells which remained uncoloured. The plates were blocked overnight at 48C with BSA (400 ìl of a 1% solution in PBS). Finally, the biotinylated bacterial suspension (100 ìl containing 5 3 10 8 cfu=ml) was added. The plates were incubated on a platform shaker for 2 h at ambient temperature. Unbound bacteria were removed by washing three times with PBS containing Tween 20 0.05% (PBST). HRP-labelled NeutrAvidin TM (Boule Nordic AB) (100 ìl of a 1 in 1500 dilution in PBS containing BSA 1%) was added to each well and incubated for 1 h at 378C. The plates were washed three times with PBS, and 100 ìl of ImmunoPure TMB substrate kit (Boule Nordic AB) were added to each well. The colour was allowed to develop for 5 min and the absorbance at 450 nm was measured with a microtitration plate reader (Multiscan, ELISA Reader). The controls used in the ELISA assay were: the heparincoated wells containing all ingredients except biotinylated bacteria and the heparin-coated wells incubated only with ImmunoPure TMB substrate kit. The OD 450 values for the controls (background) were 0.270 (SD 0.010) and 0.105 (SD 0.015), respectively. All assays were performed twice and the means and SD were calculated.
Isolation of heparin-binding proteins
The crude LiCl extracts (5±6 ml) of S. epidermidis RP 12, S. haemolyticus SM 131 and S. aureus V8 were applied to a Heparin-HiTrap column equilibrated with PBS containing Tween 20 0.1%, pH 7.2. Material retained by the column was eluted at a¯ow rate of 1 ml=min with a linear 0±2 M NaCl gradient in the same buffer. The peak fractions at 280-nm absorbance were pooled, dialysed against water (overnight at 48C), run on SDS-PAGE and silver stained (silver stain kit from BioRad).
SDS-PAGE, immunoblotting and autoradiography
S. epidermidis RP 12, S. haemolyticus SM 131 and S. aureus V8 cell-surface proteins (LiCl crude preparations or puri®ed fractions) were separated and analysed by SDS-PAGE under reducing conditions in Miniprotean II or Protean II cell slab gel vertical electrophoresis equipment (BioRad) with 12% separating gels or gradient gels (4±15%). Proteins were transferred to Immobilon1 polyvinylidone di¯uoride membrane (PVDF) (Millipore Intertech, Bedford, MA, USA) by electrotransfer and the membrane was blocked with buffer I for 15 min [18] . Strips of the membrane were incubated with biotinylated heparin or with 125 I-DTAF-heparin (3 3 10 5 cpm=ml) diluted in a washing buffer composed of PBS containing BSA 1% and Tween 20 0.1%, overnight at 208C. The strips probed with biotinylated heparin were then rinsed three times for 5 min in washing buffer and incubated for 2 h at 208C with streptavidin-HRP (diluted 1 in 3000 in washing buffer) [18] . The controls used in immunoblot assays were the strips incubated only with streptavidin-HRP, except biotinylated heparin. After washing as above the strips were incubated with 50 mM sodium acetate buffer containing 3-amino-9-ethyl carbazole 0.04% and H 2 O 2 0.015%. The blots probed with 125 I-DTAF-heparin were dried and examined by autoradiography (À708C, c. 48 h) with X-Omat AR ®lm (Eastman, Kodak). The speci®city of HBP binding [19] was tested by pre-incubation of the strips with a mixture of heparin or other polysulphated agents (100 ìg=ml ®nal concentration) and biotinylated heparin or bFGF.
To ensure that the HBP is a surface protein, bacterial cells were biotinylated before LiCl extraction and the proteins were resolved by SDS-PAGE and Western blotted with streptavidin peroxidase. LiCl extract from non-biotinylated bacterial cells probed with heparinbiotin was used as a positive control.
bFGF immunoblot binding assay
Binding assays with bFGF were performed in PBS containing BSA 1% and Tween 20 0.1% at pH 5 and 6. PVDF strips containing HBP were incubated with bFGF 50 ng=ml overnight at 208C. The strips were then rinsed three times for 5 min in washing buffer and incubated for 2 h at 208C with mouse anti-bFGF immunoglobulins. The strips were rinsed as above and incubated with peroxidase-conjugated goat antimouse immunoglobulins (diluted 1 in 1000) for 1 h at 208C. As controls, strips containing HBP incubated only with primary and secondary antibody, except bFGF, were used. After washing as above, the strips were incubated with 50 mM sodium acetate buffer containing 3-amino-9-ethylcarbazole 0.04% and H 2 O 2 0.015%.
Amino-terminal amino acid sequence
Samples of puri®ed heparin-binding proteins from S. haemolyticus SM 131 and S. epidermidis RP 12 were transferred to PVDF membranes after SDS-PAGE. These membranes were stained with Coomassie Brilliant Blue R-250 0.1% w/v in methanol 50% for membranes, and the amino-terminal amino acid sequence was analysed in a peptide sequencer ABI 476A (Foster City, CA, USA).
Iso-electric focusing and two-dimensional electrophoresis
Linear precast Immobilone DryStrips, pH 3±10 (110 3 3 3 0:5 mm) from Amersham Pharmacia Biotech (Uppsala, Sweden), were rehydrated according to the manufacturer's instructions. The crude LiCl extracts of S. epidermidis RP 12 (50 ìg of protein=strip) were loaded into a sample cup at the cathodic (basic) end of the gel strip submerged in Plusone (Drystrip cover¯uid from Amersham Pharmacia Biotech). Iso-electric focusing (IEF) was performed with a programmed voltage gradient for 21 h to a total of 34 kVh with horizontal electrofocusing apparatus (Multiphor II, Amersham Pharmacia Biotech). After IEF the strips were stored at À208C until required for the second dimension. After equilibration of the strips according to the manufacturer's instructions, the second dimension was performed on SDS polyacrylamide 8±18% gradient slab gels, at a constant voltage of 80 V for 16 h, with Protean II vertical electrophoresis equipment and Laemmli buffer system [19] . Molecular markers in the range 14±94 kDa were used (Amersham Pharmacia Biotech). The completed two-dimensional gels were either silver stained or transferred to PVDF membranes for further immunoblot assay, as described above.
Binding of TSP and vWF by HBP
Wells in a microtitration plate (Nunc MaxiSorp) were coated overnight at 48C with 100 ìl of a 5 ìg=ml solution of HBP (S. epidermidis RP 12). The wells were then blocked by incubation with BSA 3% for 1 h at 378C. TSP, vWF, Fg, Fn or Vn (0.1 ìg of protein in 100 ìl) were added to the wells followed by incubation for 2 h at room temperature. Bound serum proteins were detected by HRP-conjugated rabbit immunoglobulins against TSP, vWF, Fg, Fn or Vn diluted 1 in 1000 in PBST. The plate was washed with PBST after each incubation, developed with ImmunoPure TMB substrate and the colour was read at 450 nm. The controls used in capture ELISA assay comprised the coated wells containing all ingredients except the tested proteins and the coated wells incubated only with ImmunoPure TMB substrate kit. The OD 450 values for the controls (background) were 0.348 (SD 0.012) and 0.131 (SD 0.015), respectively. All assays were performed twice and the means and SD were calculated.
Results
GAG-binding assay
Binding of immobilised GAGs was common among CNS strains isolated from both biomaterial-associated infections and from healthy individuals. S. epidermidis RP 12 and S. haemolyticus SM 131 were selected for characterisation of heparin-binding components in CNS strains (Fig. 1) . The binding of heparin was optimal when staphylococci were cultured on BA. Maximal binding was obtained within 30 min; it was most pronounced at pH 5 and was reduced by high ionic strength (data not shown).
Isolation of heparin-binding surface proteins: SDS-PAGE and immunoblot assays
The HPLC pro®le revealed three (S. epidermidis RP 12) and four (S. haemolyticus SM 131) major peaks that were eluted at concentrations of 0.5, 0.8, 1.0 and 1.4 M NaCl. The peak materials were subjected to SDS-PAGE and, for S. epidermidis RP 12 and S. haemolyticus SM 131, four-to-®ve bands, respectively, were detected after silver staining (three-to-®ve weak bands in the high mol. wt range, 60±85 kDa) and one strong band of c. 17 kDa ( Fig. 2a and b) . A NaCl concentration of 1.4 M was needed for the elution of this protein from the heparin column, thus demonstrating the binding to be of high af®nity. This band was also detected in S. aureus V8, but was weaker than the 60-and 66-kDa HS-binding proteins reported previously ( Fig. 2c) [7] . In corresponding Western blots, several proteins were found to bind heparin, one with a molecular mass of c. 17 kDa being most prominent. This component was designated HBP (heparin-binding protein). Four other proteins bound to a lesser extent. When membranes were probed with biotin-heparin or 125 I-DTFA-heparin in PBS containing 1% BSA and Tween 20 0.1%, pH 7.2, only the major fraction with a size of c. 17 kDa retained heparin-binding ability ( Fig.  3a and b ).
Inhibition assays [20] were perfomed by incubating the strips with biotinylated heparin combined with one of the inhibitors such as heparin, suramin, fucoidan and dextran sulphate (100 ìg=ml ®nal concentration). The heparin binding to HBP was abolished by each of these inhibitors, but not by hyaluronic acid (Fig. 4a) .
In SDS-PAGE experiments combined with immunoblot assays, the LiCl-extracted proteins from biotinylated staphylococcal cells included the same 17-kDa HBP as compared with the control, the non-biotinylated staphylococcal cells, thereby demonstrating the surface location of this protein (data not shown).
bFGF immunoblot binding assay
An earlier study demonstrated that CNS may bind bFGF and some other heparin-dependent growth factors [10] , therefore the present study tested the possible binding of bFGF to HBP. As shown in Fig. 3a and b , lane 4, bFGF also bound to HBP isolated from S. epidermidis RP 12 and S. haemolyticus SM 131. The bFGF binding to HBP was almost completely abolished by heparin (Fig. 4b ).
Two-dimensional electrophoresis
By 2-D electrophoresis combined with immunoblot, HBP was shown to be acidic with a pI c. 4.6 and a molecular mass of c. 17 kDa ( Fig. 5a and b ).
N-Terminal sequencing
For the 17-kDa proteins puri®ed from S. epidermidis RP 12 and S. haemolyticus SM 131, the following sequences were obtained: MXTAHSYTXKYNGYTAN (GenBank accession no. tmpseq_AF1167348) and MATQTKGYYYSYNGYV (GenBank accession no. tmpseq_1AF169242), respectively. The N-terminal sequences of these two different staphylococcal species showed only limited identity, shown in bold. The sequences were compared in the EMBL Fasta Server Protein database; no homology with known staphylococcal cell-surface proteins or other microbial heparinbinding proteins was found. (b) Lane 1, HBP probed with biotinylated heparin; 2, HBP probed with bFGF/anti-bFGF antibody; 3, HBP preincubated with heparin (100 ìg=ml ®nal concentration) before the strip was probed with bFGF/anti-bFGF antibody; 4, HBP incubated with a mixture of heparin and bFGF (50 ng=ml) before the strip was probed with monoclonal bFGF antibody.
Binding of TSP and vWF by HBP
The broad speci®city in the binding ability of HBP was investigated by a capture enzyme-linked immunosorbent assay (ELISA). As shown in Fig. 6 , only TSP and to a lesser extent vWF (1.75-fold less than TSP) could be captured by HBP. Fg bound as well as HBP, but with a very weak af®nity, as compared with the controls. Other serum and matrix proteins such as Fn and Vn did not bind HBP (OD 450 values similar to the background level).
Discussion
Many pathogenic micro-organisms use cell surface glycolipids and glycoproteins as receptor molecules for attachment or invasion, or both, of eukaryotic cells, as well as intercellular migration processes [21] . Various ECM proteins have been implicated in microbial binding, but interactions with GAGs have been poorly studied. Recently, it has become evident that many bacteria, parasites and viruses exploit GAGs as adhesion receptors [22] and that binding to ECM proteins and GAGs may also trigger various tissue reactions, such as thrombus formation and complement activation.
Previous studies have shown that S. aureus and S. epidermidis strains speci®cally interact with ECM molecules such as Fn, Vn, Cn, TSP, vWF, lactoferrin and transferrin, all of which contain heparin-binding domains [3±6, 23, 24] . For many of these interactions, not only heparin but also other polysulphated molecules, such as fucoidan, suramin and dextran sulphate, were potent inhibitors, whereas carboxylated or nonsulphated components were not inhibitory [25] . It has also been shown that staphylococci can interact with two heparin-dependent growth factors, bFGF and PDGF [10] , which may affect tissue integration of implanted biomaterials. It is likely that these interactions can also stimulate other receptors on eukaryotic cells, which may involve secondary binding to bFGF receptors to trigger cell uptake and intracellular multiplication, as shown for gonococci [26] .
For staphylococci, it might be of conceivable bene®t to bind the different types of host cell GAGs through suitable adaptor molecules for different GAG motifs. The present study showed that staphylococci, in addition to heparin/HS, may bind other sulphated GAGs, such as chondroitin 4-sulphate and dextran sulphate (Fig. 1 ). The fact that staphylococci have the ability to bind to different sulphated polysaccharides with heterogeneous chemical structures may indicate that staphylococci express a promiscuous GAG receptor with variable af®nity for different GAGs, which is consistent with other GAG-binding receptors [11] .
The study aimed to examine the molecular mechanisms by which heparin/HS and bFGF interact with CNS strains, and a heparin-binding protein. Therefore, a HBP was puri®ed from two different CNS strains by heparin af®nity chromatography. The results suggest that HBP is a novel cell-surface protein, with a molecular mass of c. 17 kDa and a pI of c. 4.6 ( Fig.  5b) , that has af®nity for heparin, for the heparinbinding growth factor, bFGF ( Fig. 3a and b) , for TSP, for vWF and very weak af®nity for Fg ( Fig. 6) .
A notable ®nding in the present study was that the Nterminal sequence of the HBP from S. haemolyticus SM 131 was almost completely identical to the sequence obtained in this laboratory for a TSP-binding protein (c. 16 kDa) isolated from the same strain (M. Stollenwerk, unpublished observations). Furthermore, it was reported that binding to TSP and vWF by staphylococcal cells was totally blocked by heparin [23, 24] , suggesting that the heparin-binding domains of these two molecules are involved in bacterial recognition.
Broad speci®city binding proteins in S. aureus cells have been described previously [27] . By N-terminal analysis, the Vn-binding protein of S. aureus V8 showed identity with the HS-binding protein, indicating that the latter 60-kDa surface protein mediates binding of Vn as well [28] . Interestingly, HBP from S. epidermidis RP 12 showed binding not only to bFGF, but to TSP, to vWF and very weakly to Fg. TSP and vWF are secreted from activated platelets during wound healing and have been proposed to mediate staphylococcal adhesion to biomaterial surfaces in the blood stream [23, 24, 29] . Recently, it was shown that S. aureus can activate platelets and promote their deposition on the ECM. Therefore, the secreted products may also bridge the deposition of S. aureus on to the subendothelium [30] .
HBP is clearly distinct from the 20-kDa sulphated polysaccharide puri®ed from the extracellular slime layer of S. epidermidis [31] , which behaves as a 30-kDa band in SDS-PAGE and immunoblotting experiments on crude slime. Moreover, the HBP could not be detected in extracts prepared by sonication from S. epidermidis cells grown on tissue-culture dishes in TS (data not shown), as proposed for the isolation of a capsular polysaccharide/adhesin (PS/A, c. 28 kDa) [32] . As shown by the N-terminal sequence, S. epidermidis HBP is distinct from the previously reported 19-kDa Fg-binding protein of S. epidermidis, puri®ed from culture supernates [33] . The relationship of HBP to other cell-surface components in CNS and its binding speci®city merit further investigation.
As binding of heparin was common among CNS strains isolated from both patients and healthy carriers, any role of the expression of HBP for staphylococcal pathogenicity in man is unclear at present. As with binding of ECM molecules, including Fn, Vn, TSP and type IV Cn, GAG binding to staphylococcal cells may allow coating of these bacteria with host molecules, which may prevent attack by phagocytes and the immune system. Heparin binding by microbes was recently highlighted by Duensing et al. as a novel strategy in microbial pathogenesis that complements the classical virulence strategy [34] . This mechanism enables different bacterial species that bind heparin/HS and other GAGs to recruit structurally and functionally diverse bioactive host proteins, including adhesive glycoproteins (Fn and Vn), in¯ammatory and immunomodulatory mediators, and growth factors [34] .
Adhesive proteins, such as Fn and Vn, have been implicated as intermediates in bacterial interactions with host cell integrin receptors, resulting in bacterial colonisation and invasion of epithelial cells [4] . From our ongoing studies, we also envisage a possible role for CNS heparin-binding abilities in the initial attachment of staphylococci to endothelial cells expressing both HS and TSP on their surface [35] . The interaction of staphylococci with GAGs may thus be important for ef®cient infection of eukaryotic cells by staphylococci. Furthermore, the binding of bFGF to staphylococcal cells might interfere with repair processes in the infected tissue.
In summary, the present study has demonstrated that staphylococci express surface components which recognise heparin-related polysaccharides, a heparindependent growth factor, bFGF, TSP and vWF. The biological importance of these interactions and their possible role in staphylococcal infections remain to be further investigated. The use and development of implanted arti®cial biomaterials is hampered by infectious complications. A better understanding of the pathogenesis of these infections might lead to interventions that directly attenuate bacterial virulence or modulate host responses, and ultimately to improved methods of bioimplantation.
